Download - Endocarditis 2005 12
![Page 1: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/1.jpg)
Infective Endocarditis
Matthew Leibowitz, MD
David Geffen School of Medicine at UCLA
Division of Infectious Diseases
![Page 2: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/2.jpg)
Epidemiology
• 10-20,000 cases per year in the US
• Male:Female ratio 1.7:1
• New trends– Mean age was 30 in 1926, now > 50% of
patients are over 60– Decline in incidence of rheumatic fever– More prosthetic valves– More nosocomial cases, injected drug use– More staphylococcal infection
![Page 3: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/3.jpg)
Epidemiology
• Mitral valve alone 28-45%
• Aortic valve alone 5-36% (bicuspid valve in 20% of all native valve IE)
• Both mitral and aortic valves 0-36%
• Tricuspid valve 0-6%
• Pulmonic valve <1%
• Right and left sided 0-4%
![Page 4: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/4.jpg)
Classification
• OLD– Subacute Bacterial Endocarditis
• Death in 3-6 months
– Acute Bacterial Endocarditis• Death in < 6 weeks
• NEW– Native Valve Endocarditis– Prosthetic Valve Endocarditis
![Page 5: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/5.jpg)
Pathogenesis
• Alteration of the valvular endothelial surface leading to deposition of platelets and fibrin
• Bacteremia with seeding of non-bacterial thrombotic vegetation (NBTE)
• Adherence and growth, further platelet and fibrin deposition
• Extension to adjacent structures– Papillary muscle, aortic valve ring abscess,
conduction system
![Page 6: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/6.jpg)
Pathogenesis
• Low pressure side of structural lesion– Atrial side of mitral valve (MR)– Ventricular side of aortic valve (AR, AS with R)– Congenital abnormality (MV prolapse, bicuspid AV)– Scarring from rheumatic heart disease or sclerosis
as a consequence of aging– Prosthetic valves
• Other turbulence, high-velocity jets– Ventricular septal defect– Stenotic valve
• Direct mechanical damage from catheters, pacemaker leads
![Page 7: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/7.jpg)
Pathogenesis
• Transient bacteremia– Traumatization of mucosal surface
colonized with bacteria (oral, GI)– Low grade, cleared in 15-30 minutes– Susceptibility to complement-mediated
bacterial killing
• Leads to concept of prophylaxis
![Page 8: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/8.jpg)
![Page 9: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/9.jpg)
Microbiology• Staphylococcus aureus (30-40%)• Viridans group streptococci (18%)• Enterococci (11%)• Coagulase-negative staphylococci (11%)• Streptococcus bovis (7%)• Other streptococci (5%)• Non-HACEK Gram negatives (2%)• HACEK Organisms (2%)• Fungi (2%)• “Culture negative” (2-20%)
![Page 10: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/10.jpg)
Characteristics of Causative Organisms
• Adherence factors critical for growth in the vegetation– Can adhere to damaged valves (Staph, Strep and
Enterococci have adhesins that mediate attachment)
– Staph adhesin binds fibrinogen and fibronectin– Bacteria trigger tissue-factor production from local
monocytes and induce platelet aggregation so the organisms become enveloped in the vegetation
– Protection from immune clearance leads to large numbers of bacteria (109-1010 per g of tissue)
![Page 11: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/11.jpg)
Risk Factors
• Structural heart disease– Rheumatic, congenital, aging– Prosthetic heart valves
• Injected drug use
• Invasive procedures (?)
• Indwelling vascular devices
• Other infection with bacteremia (e.g. pneumonia, meningitis)
• History of infective endocarditis
![Page 12: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/12.jpg)
Clinical Manifestations• Symptoms
– Fever, sweats, chills– Anorexia, malaise, weight loss
• Signs– Anemia (normochromic, normocytic)– Splenomegaly– Microscopic hematuria, proteinuria– New or changing heart murmur, CHF– Embolic or immunologic dermatologic signs– Hypergammaglobulinemia, elevated ESR, CRP,
RF
![Page 13: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/13.jpg)
![Page 14: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/14.jpg)
Cardiac Pathologic Changes
• Vegetations on valve closure lines
• Destruction and perforation of valve leaflet
• Rupture of chordae tendinae, intraventricular septum, papillary muscles
• Valve ring abscess
• Myocardial abscess
• Conduction abnormalities
![Page 15: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/15.jpg)
S. Aureus mitral valve vegetation, anterior leaflet
![Page 16: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/16.jpg)
![Page 17: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/17.jpg)
Pathologic Changes
• Kidney– Immune complex glomerulonephritis– Emboli with infarction, abscess
• Aortic mycotic aneurysms
• Cerebral embolism– Infarction, abscess, mycotic aneurysms– Purulent meningitis is rare
![Page 18: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/18.jpg)
![Page 19: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/19.jpg)
Pathologic Changes
• Splenic enlargement, infarction• Septic or bland pulmonary embolism• Skin
– Petechiae– Osler nodes: diffuse infiltrate of neutrophils, and
monocytes in the dermal vessels with immune complex deposition. Tender and erythematous
– Janeway lesions: septic emboli with bacteria, neutrophils and SQ hemorrhage and necrosis. Blanching and non-tender. Palms and soles
![Page 20: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/20.jpg)
![Page 21: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/21.jpg)
![Page 22: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/22.jpg)
![Page 23: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/23.jpg)
![Page 24: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/24.jpg)
Case Definition
• 1977 Pelletier and Petersdorf criteria
• 1981 von Reyn criteria
• 1994 Duke criteria
• 2000 Modified Duke criteria
![Page 25: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/25.jpg)
Modified Duke Criteria• Major Criteria
– Positive blood cultures with typical organisms
– Persistently positive blood cultures– Evidence of Endocardial involvement
• Positive Echocardiogram– Oscillating intracardiac mass– Abscess– Dehiscence of prosthetic valve
• New Valvular regurgitation
![Page 26: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/26.jpg)
Modified Duke Criteria
• Minor Criteria– Predisposition (valvular disease or IDU)– Fever– Vascular phenomena (Arterial emboli,
septic pulmonary infarcts, intracranial hemorrhage, Osler, Janeway)
– Immunologic phenomena (GN, Osler, Roth spots, Rheumatoid Factor)
![Page 27: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/27.jpg)
Modified Duke Criteria
• Definite IE– Pathologic criteria– Clinical criteria
• 2 Major Criteria OR• 1 Major and 3 minor Criteria OR• 5 Minor Criteria
• Possible IE• 1 Major and 1 Minor OR• 3 Minor
• Rejected IE
![Page 28: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/28.jpg)
Blood Cultures
• MULTIPLE BLOOD CULTURES BEFORE EMPIRIC THERAPY
• If not critically ill– 3 blood cultures over 12-24 hour period– ? Delay therapy until diagnosis confirmed
• If critically ill– 3 blood cultures over one hour
• No more than 2 from same venipuncture
• Relatively constant bacteremia
![Page 29: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/29.jpg)
“Culture Negative” IE
• Less common with improved blood culture methods
• Special media required– Brucella, Mycoplasma, Chlamydia,
Histoplasma, Legionella, Bartonella
• Longer incubation may be required– HACEK
• Coxiella burnetii (Q Fever), Trophyrema whipplei will not grow in cell-free media
![Page 30: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/30.jpg)
HACEK
• Haemophilus aphrophilus, H. paraphrophilus, parainfluenzae
• Actinobacillus actinomycetemcomitans
• Cardiobacterium hominis
• Eikenella corrodens
• Kingella kingae
![Page 31: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/31.jpg)
Other microbiologic methods
• PCR– Coxiella burnetii– Tropheryma whipplei– Bartonella henselae
• Serology– Coxiella burnetii– Bartonella– Brucella– Legionella– Chlamydophila psittaci
![Page 32: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/32.jpg)
Echocardiography
• Transthoracic– Relatively low sensitivity– Good specificity
• Transesophageal– Detection of valve ring abscess (87% vs.
28% sensitivity for TTE)– Detection of prosthetic valve IE
![Page 33: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/33.jpg)
When to go to TEE first?
• Limited thoracic windows = TTE low sensitivity
• Prosthetic valves
• Prior valvular abnormality
• S. aureus bacteremia and suspected IE
• Bacteremia with organisms likely to cause IE
= high prior probability of IE
![Page 34: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/34.jpg)
Other tests
• Electrocardiogram– Conduction delays– Ischemia or infarction
• Chest X-ray– Septic emboli in right-sided IE– Valve calcification– CHF
![Page 35: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/35.jpg)
Treatment of IE
• Native vs. Prosthetic Valve
• Bactericidal therapy is necessary
• Eradication of bacteria in the vegetation– May be metabolically inactive (stationary
phase)– May need higher concentrations of
antimicrobial agents
![Page 36: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/36.jpg)
Antimicrobial Therapy
• Most patients are afebrile in 3-5 days
• Long duration of therapy (4-6 weeks or more)
• Combination therapy most important for– Shorter course regimens– Enterococcal endocarditis– Prosthetic valve infections
![Page 37: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/37.jpg)
Native Valve IE
• Viridans Streptococci and S. bovis– Aqueous Penicillin G 12-20 million
units/day continuously or divided q4 or q6 for 4 weeks
– If intermediate susceptibility to penicillin, aqueous penicillin G 24 million units or ceftriaxone 2 g q24 PLUS aminoglycoside for the first 2 weeks
![Page 38: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/38.jpg)
Native Valve IE
• Aminoglycosides for synergy– Low concentrations are adequate (1-3
mcg/ml)– Gentamicin 3 mg/kg divided q12 or q8– Little data for q24 dosing
![Page 39: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/39.jpg)
Native Valve IE
• Enterococci, ampicillin sensitive– High rates of failure– β-lactams are bacteriostatic, must combine with
aminoglycoside for optimal therapy– High-level gentamicin resistance occurs in 35%
• High-dose ampicillin for 8-12 weeks
• Enterococci, ampicillin resistant– Vancomycin plus gentamicin
• Enterococci, vancomycin resistant– Linezolid or daptomycin– Penicillin + vancomycin + gentamicin ?
![Page 40: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/40.jpg)
Native Valve IE
• S. aureus– Penicillinase-resistant semi-synthetic
penicillin (oxacillin or nafcillin) 1.5-2 g IV q4 or cephalosporin (cefazolin 1-2 g IV q8) for 4-6 weeks
– Aminoglycoside synergistic but does not affect survival, not recommended
– Short course in right-sided IE• 2 weeks of semi-synthetic penicillin and
aminoglycoside
![Page 41: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/41.jpg)
Native Valve IE
• Methicillin-resistant S. aureus– Vancomycin is bacteriostatic– Vancomycin plus aminoglycoside or
rifampin– Daptomycin– Linezolid
![Page 42: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/42.jpg)
Native Valve IE
• HACEK– Ceftriaxone 2 g IV q 24 x 4-6 weeks
• Fungal– Amphotericin– Fluconazole– Caspofungin, little data– Surgery usually necessary 1-2 weeks into
treatment
![Page 43: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/43.jpg)
Native Valve IE
• Indications for surgery– Refractory CHF– More than one systemic embolic event– Uncontrolled infection– Physiologically significant valvular
dysfunction– Ineffective antimicrobial therapy (e.g.
fungal)– Local suppurative complications– Mycotic aneurysm
![Page 44: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/44.jpg)
Prosthetic Valve IE
• Staphylococci most common– Coagulase negative staphylococci
• Enterococcus
• Nutritonally variant streptococci
• Fungi
![Page 45: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/45.jpg)
Prosthetic Valve IE
• Risk is greatest in the first 3 months and first year (early PV IE)– Coagulase-negative staphylococci in early
endocarditis, S. aureus– Late-onset more similar to native valve
disease in microbiology but more coagulase-negative staphylococci. Valve is endothelialized
![Page 46: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/46.jpg)
Prosthetic Valve IE
• TEE should be used first
• Staphylococci– Vancomycin or oxacillin plus rifampin for at
least six weeks, gentamicin for the first two weeks (3 mg/kg q24)
– Rifampin started at least 2 days after 2 other agents to avoid resistance
![Page 47: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/47.jpg)
![Page 48: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/48.jpg)
![Page 49: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/49.jpg)
Prophylaxis of IE
• Uncertainty and controversy
• No randomized trials
• Indirect evidence (uncontrolled clinical series, case-control studies)
• Decision analysis
![Page 50: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/50.jpg)
![Page 51: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/51.jpg)
![Page 52: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/52.jpg)
![Page 53: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/53.jpg)
![Page 54: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/54.jpg)
Clinical Case
• 43 yo man ESRD, Cadaveric Renal Transplant 2004
• Recurrent UTIs, placement of nephrostomy tube
• Fevers, chills, altered mental status, sepsis syndrome
• Bradycardia to 35 and increased PR
![Page 55: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/55.jpg)
Clinical Case• Urine with MRSA, 4/4 blood cultures with MRSA• Initial TTE: EF 35-45%, thickened AV with moderate
AS, thickened or calcified MV mild MR– “Compared with last previous echo, 3/3/00, there is no
significant change. In the presence of valvular thickening, cannot rule out endocarditis.
• Next day TEE– thickened AV, mild to moderate AS, no AR. 2 vegetations
~1 cm on ventricular side– Markedly thickened MV, large mobile vegetation >4cm on
atrial side anterior leaflet, possible second vegetation on posterior leaflet, mild MR
![Page 56: Endocarditis 2005 12](https://reader034.vdocuments.us/reader034/viewer/2022052619/5564cc2fd8b42a0a178b4bf7/html5/thumbnails/56.jpg)
Clinical case
• Renal allograft removed the following day with abscess
• Replacement of AV and MV and resection of left ventricular abscess cavity two days later